Form 4: Verve Therapeutics Officer Disposes Shares Following Eli Lilly Acquisition

Verve Therapeutics' Chief Administrative Officer, Joan Nickerson, disposed of all common stock, stock options, and restricted stock units following the company's acquisition by Eli Lilly and Company.

Summary

• Verve Therapeutics, Inc. (VERV) was acquired by Eli Lilly and Company ('Parent') through its indirect wholly-owned subsidiary, Ridgeway Acquisition Corporation ('Purchaser').
• The merger became effective on July 25, 2025, at which point Verve Therapeutics, Inc. became a wholly-owned subsidiary of Eli Lilly and Company.
• Tendering stockholders received $10.50 per share in cash ('Cash Consideration') plus one non-tradable contingent value right ('CVR').
• Each CVR represents a contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, upon the achievement of a specified milestone relating to Verve's business.
• Joan Nickerson, Chief Administrative Officer, disposed of 17,420 shares of common stock as a result of the merger.
• All outstanding stock options with an exercise price less than the Cash Consideration were cancelled, with holders receiving cash equal to the difference between the Cash Consideration and the exercise price, multiplied by the number of shares, plus one CVR per share.
• Stock options with an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment were cancelled, with holders entitled to receive a cash payment equivalent to the CVR payment when made.
• All unvested Restricted Stock Units (RSUs) were cancelled, with holders receiving cash equal to the Cash Consideration multiplied by the number of shares subject to the RSU, plus one CVR per RSU.
• Following these transactions, Joan Nickerson beneficially owns 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 8

Explanation: The filing reflects the successful completion of an acquisition, which typically provides a premium to shareholders and liquidity for insiders. The CVR adds potential upside, indicating a favorable outcome for the company's equity holders.

Positives

• The acquisition by Eli Lilly and Company provides liquidity and a premium for Verve Therapeutics shareholders.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside for former shareholders and equity holders upon the achievement of a specified milestone.

Risks

• The contingent payment of up to $3.00 per CVR is dependent on the achievement of a specific milestone, meaning the full potential value is not guaranteed.

Future Outlook

The future outlook for former Verve Therapeutics shareholders includes the potential to receive an additional contingent payment of up to $3.00 per CVR upon the achievement of a specified business milestone. Verve Therapeutics, Inc. now operates as a wholly-owned subsidiary of Eli Lilly and Company.

Industry Context

This transaction reflects a common trend in the biotechnology and pharmaceutical industries where larger, established pharmaceutical companies acquire smaller, innovative biotech firms to expand their pipelines and intellectual property portfolios. The use of a Contingent Value Right (CVR) is a mechanism often employed in such acquisitions to bridge valuation gaps and share future development risks or rewards.

Comparison to Industry Standards

• NA This Form 4 reports a transactional event (insider's disposition of shares due to a merger) rather than operational results or financial performance that would typically be benchmarked against industry standards. The merger terms themselves (cash premium, CVR structure) are common in biotech acquisitions, but specific comparative details are not provided in this filing.

Corporate Governance

Related Party Transactions

• The entire transaction detailed in the filing, the acquisition of Verve Therapeutics by Eli Lilly and Company, constitutes a significant related party transaction as Verve became a subsidiary of Eli Lilly.

Stakeholder Impact

• Shareholders: Received cash consideration and Contingent Value Rights (CVRs) for their shares, providing liquidity and potential future upside.
• Employees (including Joan Nickerson): Had their equity holdings (stock options, RSUs) converted into cash and CVRs, providing a liquidity event for their vested and unvested equity.

Next Steps

• Achievement of the specified milestone for the Contingent Value Right (CVR) payment.

Key Dates

Keywords

Verve Therapeutics, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals, Stock Options, Restricted Stock Units